Baumer

Baumer EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Baumer (BALM4.SA) as of Nov 9, 2026 is 36.00 M BRL. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 22.00 M BRL — a change of 63.64% (higher).

EBITDA

36.00 MBRL

YoY

63.64%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Baumer is 2024 36.00 M BRL. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Baumer was 2023 22.00 M BRL. It decreases by 63.64% higher compared to the previous year.

The Baumer EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
3.32 M BRL
Jan 1, 2018
5.40 M BRL
Jan 1, 2019
9.17 M BRL
Jan 1, 2020
17.06 M BRL
Jan 1, 2021
12.24 M BRL
Jan 1, 2022
17.88 M BRL
Jan 1, 2023
22.00 M BRL
Jan 1, 2024
36.00 M BRL
The Baumer EBITDA history
YEAREBITDAYoY
36.00 MBRL+63.64%
22.00 MBRL+23.03%
17.88 MBRL+46.15%
12.24 MBRL-28.28%
17.06 MBRL+86.01%
9.17 MBRL+69.93%
5.40 MBRL+62.46%
3.32 MBRL-64.14%
9.26 MBRL-35.24%
14.31 MBRL-17.00%
17.23 MBRL—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Baumer Stock analysis

What does Baumer do? Baumer SA generates revenue through the sale of medical equipment and solutions across its four business units. The Orthopedic unit produces and sells orthopedic implants and instruments, while the Hospital unit manufactures equipment for hospitals and industries including pharmaceutical, chemical, cosmetic, and food sectors. The Genius unit focuses on biomaterials, and the Brown unit supplies laundry equipment for hospitals, industrial, and hotel settings. The company's subsidiaries, Hospitalar Sul Ltda and Waldsea Investment SA, support its operations as of December 31, 2011. The primary buyers of Baumer SA's products include hospitals, pharmaceutical companies, chemical manufacturers, cosmetic firms, and food industry businesses. Additionally, industrial and hotel sectors purchase the laundry equipment from the Brown unit. The company's technical assistance services for medical apparatus also contribute to its revenue stream. Baumer SA's business model relies on direct sales of its specialized equipment and solutions to healthcare and industrial clients. The firm's product portfolio spans orthopedic care, hospital infrastructure, biomaterials, and laundry systems, catering to both medical and non-medical industrial applications. This diversified approach allows the company to serve multiple segments within the health and industrial markets. Baumer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Baumer stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Baumer is 36.00 M BRL in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Baumer changed from 22.00 M BRL to 36.00 M BRL, representing a 63.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Baumer since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s BRL is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Baumer historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Baumer

All Key Metrics — Baumer